Replimune’s melanoma drug would have been rejected again if not for senior CBER official
RegulatoryTudriqevNegative
AI Analysis
Summary
Replimune's melanoma drug Tudriqev faced rejection from the FDA's primary review team for failing to adequately address previously identified deficiencies; approval was only secured through intervention by a senior CBER official.
Outcome Details
FDA primary review team found deficiencies not adequately addressed; approval was contingent on senior CBER official intervention
Importance:8/10
Sentiment:
-0.70
FDA rejectionregulatory setbackmelanomaTudriqevCBERdeficiency letter
Related Companies
Read the original article
Published by BioSpace on September 3, 2026 11:29 AM